ASCO Guideline Update | 合法藥品大搜索

由 F Yang 著作 · 2019 · 被引用 4 次 — The modified FOLFIRINOX regimen is superior to gemcitabine as adjuvant therapy for resected pancreatic cancer, and should be a new standard of care for this ... Read More

由 L Cavanna 著作 · 2019 · 被引用 8 次 — Purpose: Metastatic pancreatic adenocarcinoma has a very poor prognosis. Although irinotecan, oxaliplatin and leucovorin-modulated ... Read More

Dilute in 500 to 1000 mL 0.9% NS or D5W¶ and administer as a continuous IV infusion over 46 hours. To accommodate an ambulatory pump for outpatient treatment, ... Read More

Bookmark. Tools. © 2021 UpToDate, Inc. and/or its affiliates. All Rights Reserved. Modified FOLFIRINOX chemotherapy for pancreatic cancer ... Read More

由 H Tong 著作 · 2018 · 被引用 35 次 — In general, the modified FOLFIRINOX regimen could provide good survival benefits for patients with advanced pancreatic cancer by increasing the ... Read More

由 X Li 著作 · 2017 · 被引用 32 次 — FOLFIRINOX chemotherapy has shown remarkable responses in patients with metastatic pancreatic cancer (MPC), and has significantly improved ... Read More

由 JD Mizrahi 著作 · 2020 · 被引用 16 次 — Background: Although FOLFIRINOX (5-Fluorouracil + leucovorin + irinotecan + oxaliplatin) is now the standard of care for patients (pts) with metastatic ... Read More

由 T Conroy 著作 · 2018 · 被引用 881 次 — Conclusions. Adjuvant therapy with a modified FOLFIRINOX regimen led to significantly longer survival than gemcitabine among patients with ... Read More

Patients with metastatic pancreatic cancer (MPC) were treated with modified FOLFIRINOX every 2 weeks as follows: oxaliplatin 85 mg m 2 infused over 120 min, ... Read More

2019年6月18日 — ASCO Guideline Update: Modified FOLFIRINOX Is Preferred as Adjuvant Chemotherapy in Patients With Resected Pancreatic Adenocarcinoma · Get Cancer ... Read More